Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its public reporting. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, and its filings offer insight into the development and commercialization of IMCIVREE (setmelanotide) and related MC4R agonist programs.
Investors can review current reports on Form 8‑K in which Rhythm discusses material events such as quarterly and annual financial results, FDA and EMA regulatory milestones, equity offerings, and amendments to its certificate of incorporation. For example, the company has filed 8‑Ks describing FDA Priority Review and PDUFA goal dates for a supplemental New Drug Application for IMCIVREE in acquired hypothalamic obesity, as well as an 8‑K detailing an underwritten public offering of common stock and intended use of proceeds.
While this page focuses on current reports and other SEC documents, it also serves as a gateway to Rhythm’s periodic reports, where investors typically find detailed information on revenue from global sales of IMCIVREE, research and development expenses, selling, general and administrative expenses, cash position and funding runway. These filings also describe clinical programs in acquired and congenital hypothalamic obesity, genetically caused MC4R pathway diseases and Prader-Willi syndrome, along with investigational agents bivamelagon and RM-718.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as changes in operating expenses, financing transactions, or significant regulatory updates. Real-time ingestion from EDGAR helps surface new Rhythm filings quickly, and users can also monitor items that may relate to executive or director activity when Forms 3, 4 or 5 are filed. This combination of original documents and AI explanations is designed to make RYTM’s complex biopharmaceutical disclosures more accessible to a broad range of investors.
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting beneficial ownership of 0 shares (0%) of Rhythm Pharmaceuticals Inc common stock following an internal realignment. The filing states certain Vanguard subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538. The filing lists the issuer address as 500 Boylston Street, Boston, MA and is signed by Ashley Grim on 03/27/2026.
Rhythm Pharmaceuticals reported that a key European regulatory committee has issued a positive opinion supporting an expansion of the current marketing authorization for IMCIVREE (setmelanotide). The recommendation covers treatment of obesity and control of hunger in adults and children 4 years and older with acquired hypothalamic obesity caused by hypothalamic injury or impairment.
The opinion from the EMA’s Committee for Medicinal Products for Human Use will now be reviewed by the European Commission, which decides on marketing authorizations in the European Union. A final decision on the proposed label expansion is anticipated in the second quarter of 2026.
Rhythm Pharmaceuticals reports that the U.S. Food and Drug Administration has approved an expanded indication for IMCIVREE (setmelanotide) to treat adults and children aged 4 years and older living with acquired hypothalamic obesity. IMCIVREE is now described as the first and only FDA‑approved therapy for this rare condition.
The approval is based on the pivotal Phase 3 TRANSCEND trial in 142 patients, where setmelanotide achieved a placebo‑adjusted -18.4% reduction in BMI. Patients on setmelanotide (n=94) saw a -15.8% BMI change versus a +2.6% increase on placebo (n=48) at 52 weeks (p<0.0001). Setmelanotide was generally well tolerated; common adverse events included skin hyperpigmentation, nausea, vomiting and headache. Rhythm estimates about 10,000 people in the U.S. are living with acquired hypothalamic obesity, highlighting a meaningful new commercial and clinical opportunity for its lead asset.
Rhythm Pharmaceuticals reported topline results from its global Phase 3 EMANATE trial of setmelanotide in four MC4R-pathway genetic obesity substudies. Using the predefined analysis of mean percent BMI change at Week 52 in the modified intent-to-treat population with multiple imputation, none of the substudies met their primary endpoint, with placebo‑adjusted BMI reductions of –4.3% in POMC/PCSK1 heterozygotes, –3.6% in LEPR heterozygotes, –4.0% in SRC1 (NCOA1) and –1.7% in SH2B1, all with non‑significant p‑values.
Post hoc analyses using last observation carried forward showed statistically significant, larger BMI reductions in the POMC/PCSK1 and SRC1 groups, including least‑squares mean differences of –5.5% and –6.2%, and placebo‑adjusted reductions of –9.7% and –8.0% in genetically confirmed completers. No new safety signals emerged; adverse events were consistent with prior experience, mainly skin hyperpigmentation, injection‑site reactions, nausea, vomiting and headache. Rhythm plans further analysis of EMANATE and to advance next‑generation MC4R agonists bivamelagon and RM‑718 in selected genetic indications.
Rhythm Pharmaceuticals director Edward T. Mathers reported an internal restructuring of his related holdings. NEA Partners 13, L.P. made a pro rata, no‑consideration distribution of Rhythm common stock to its limited partners, and the Edward Timothy Mathers Revocable Trust received 4,199 shares.
Mathers is trustee of this trust, which now indirectly holds 14,168 shares of Rhythm common stock, while he also directly holds 7,000 shares
Rhythm Pharmaceuticals corporate controller Christopher Paul German reported option exercises and share sales. On March 4, 2026, he exercised stock options for 1,500 shares at an exercise price of $17.97 per share, converting derivative awards into common stock.
That same day, he sold 5,614 shares of common stock in open-market transactions at $89.56 per share, leaving 160 shares of common stock held directly after the sale. A footnote notes that his holdings include 21 shares purchased through the employee stock purchase plan and that the options vest in scheduled installments through March 20, 2027.
Rhythm Pharmaceuticals executive Yann Mazabraud received a grant of 35,000 stock options on March 2, 2026. The options carry an exercise right to buy company stock at a set price and were awarded at no cost. They vest in 16 substantially equal installments, each after three full months of continued service to the company, tying the award to ongoing employment.
Rhythm Pharmaceuticals director Edward T. Mathers reported an other type of insider transaction involving common stock. On March 2, 2026, NEA Partners 13, L.P. made a pro rata, no‑consideration distribution of Rhythm shares to its limited partners, and the Edward Timothy Mathers Revocable Trust received 4,198 shares. Mathers is trustee of this trust, which held 9,969 Rhythm shares indirectly after the transaction, while he also held 7,000 shares directly. He disclaims beneficial ownership of any portion of the trust’s holdings in which he has no pecuniary interest.
RYTM filing reports a proposed sale of 64,540 common shares on 03/04/2026 described as an exercise of options under a registered plan. The filing also records a sale of 35,460 common shares by Camille L. Bedrosian on 03/03/2026 for $3,209,778.92.
Rhythm Pharmaceuticals Corporate Controller and Chief Accounting Officer Christopher Paul German reported routine equity compensation activity. On March 1, 2026, he exercised 1,162 restricted stock units, receiving the same number of common shares at $0.00 per share. Of these, 342 common shares were automatically withheld at $94.94 per share to cover tax obligations, rather than sold on the open market. After these transactions, he directly owned 4,253 shares of common stock. The underlying restricted stock units vest in four equal 25% installments on March 20, 2024, March 20, 2025, March 1, 2026, and March 1, 2027, contingent on continued service.